Rigel Pharmaceuticals (RIGL) Operating Leases (2019 - 2026)

Rigel Pharmaceuticals' Operating Leases history runs 8 years deep, the most recent figure standing at $228000.0 for Q1 2026.

• In Q1 2026, Operating Leases fell 73.61% year-over-year to $228000.0; the TTM figure through Mar 2026 stood at $228000.0 (down 73.61% YoY), while the FY2025 annual figure was $395000.0, changed N/A from the prior year.
• Operating Leases for Q1 2026 stood at $228000.0, down from $395000.0 in the prior quarter.
• The five-year high for Operating Leases was $8.3 million in Q1 2022, with the low at $100000.0 in Q1 2024.
• The 5-year median for Operating Leases is $592000.0 (2023), against an average of $1.2 million.
• The sharpest annual moves came in 2023 and 2025: Operating Leases slumped 90.34% in 2023, then soared 764.0% in 2025.
• Rigel Pharmaceuticals' Operating Leases stood at $972000.0 in 2022, then slumped by 70.68% to $285000.0 in 2023, then plunged by 64.91% to $100000.0 in 2024, then jumped by 295.0% to $395000.0 in 2025, then slumped by 42.28% to $228000.0 in 2026.
• Business Quant data shows RIGL's Operating Leases at $228000.0 in Q1 2026, $395000.0 in Q4 2025, and $556000.0 in Q3 2025.